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ABSTRACT While complex intra- and interspecies microbial community dynamics
are apparent during chronic infections and likely alter patient health outcomes, our
understanding of these interactions is currently limited. For example, Pseudomonas
aeruginosa and Staphylococcus aureus are often found to coinfect the lungs of pa-
tients with cystic fibrosis (CF), yet these organisms compete under laboratory condi-
tions. Recent observations that coinfection correlates with decreased health out-
comes necessitate we develop a greater understanding of these interbacterial
interactions. In this study, we tested the hypothesis that P. aeruginosa and/or S. au-
reus adopts phenotypes that allow coexistence during infection. We compared com-
petitive interactions of P. aeruginosa and S. aureus isolates from mono- or coinfected
CF patients employing in vitro coculture models. P. aeruginosa isolates from monoin-
fected patients were more competitive toward S. aureus than P. aeruginosa isolates
from coinfected patients. We also observed that the least competitive P. aeruginosa
isolates possessed a mucoid phenotype. Mucoidy occurs upon constitutive activation
of the sigma factor AlgT/U, which regulates synthesis of the polysaccharide alginate
and dozens of other secreted factors, including some previously described to kill
S. aureus. Here, we show that production of alginate in mucoid strains is sufficient to
inhibit anti-S. aureus activity independent of activation of the AlgT regulon. Alginate
reduces production of siderophores, 2-heptyl-4-hydroxyquinolone-N-oxide (HQNO), and
rhamnolipids—each required for efficient killing of S. aureus. These studies demonstrate
alginate overproduction may be an important factor driving P. aeruginosa coinfection
with S. aureus.
IMPORTANCE Numerous deep-sequencing studies have revealed the microbial
communities present during respiratory infections in cystic fibrosis (CF) patients are
diverse, complex, and dynamic. We now face the challenge of determining the influ-
ence of these community dynamics on patient health outcomes and identifying can-
didate targets to modulate these interactions. We make progress toward this goal
by determining that the polysaccharide alginate produced by mucoid strains of
P. aeruginosa is sufficient to inhibit multiple secreted antimicrobial agents produced
by this organism. Importantly, these secreted factors are required to outcompete
S. aureus, when the microbes are grown in coculture; thus we propose a mechanism
whereby mucoid P. aeruginosa can coexist with S. aureus. Finally, the approach used
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here can serve as a platform to investigate the interactions among other CF patho-
gens.
KEYWORDS Pseudomonas aeruginosa, Staphylococcus aureus, biofilm, cystic fibrosis,
mucoid, polymicrobial
Cystic fibrosis (CF) is the most common fatal, inherited disease among Caucasians.Progressive decline in pulmonary function, resulting from decreased mucociliary
clearance, persistent bacterial infections of the airway, and neutrophil-dominated
inflammation, is the predominant cause of morbidity and mortality for CF patients (1).
CF respiratory infections are notable for their complex polymicrobial nature and
recalcitrance to antimicrobial therapeutics. Patients are colonized throughout their lives
with a diverse community of pathogens of viral, bacterial, and fungal origins (2).
Unfortunately, these infections are rarely eradicated, and patients suffer from frequent
exacerbations, hospitalization, and often ineffective treatments with intravenous and
inhaled antibiotics. While the importance of interspecies interactions during infection is
increasingly appreciated, most studies are still performed with single microbial species
in culture, and our knowledge of polymicrobial interactions is limited.
Pseudomonas aeruginosa and Staphylococcus aureus are two of the most prevalent
and often the most problematic pathogens in CF. Both S. aureus and P. aeruginosa
exhibit intrinsic and acquired antibiotic resistance, making these infections difficult to
treat (3, 4). S. aureus is among one of the earliest pathogens to infect pediatric CF
patients, whereas P. aeruginosa infections are intermittent early on until a dominant
clone emerges and P. aeruginosa becomes the predominant pathogen later in life (5).
This inverse pattern of infection has led many investigators to speculate that P. aerugi-
nosa eliminates S. aureus during infection—perhaps outcompeting S. aureus for limited
nutrients in the lung and/or producing antimicrobial factors to kill S. aureus directly
(recently reviewed in reference 6). These hypotheses are supported by several in vitro
studies that demonstrate P. aeruginosa can inhibit the growth or reduce the viability of
S. aureus through multiple mechanisms, including sequestration of iron and inhibition
of S. aureus respiration via production of the secondary metabolite 2-heptyl-4-
hydroxyquinoline-N-oxide (HQNO) (7–16).
Importantly, despite evidence that P. aeruginosa outcompetes S. aureus in vitro, CF
patients acquire coinciding pulmonary infections with P. aeruginosa and S. aureus. We
and others have observed a correlation between coinfection and poor patient outcome,
whereby infection with both P. aeruginosa and S. aureus correlates with increased
pulmonary exacerbations and lower baseline forced expiratory volumes of the lung in
1 s (FEV1) compared to patients who were monoinfected with only S. aureus or
P. aeruginosa (17–19). Examination of 234 CF patients at EmoryChildren’s Center for
Cystic Fibrosis and Airways Disease Research revealed that 73 patients (31%) were
coinfected with P. aeruginosa and S. aureus (17). Moreover, recent data demonstrate
higher rates of infection with S. aureus in patients later in life than previously appre-
ciated (20). These observations suggest our currently held model that P. aeruginosa
outcompetes S. aureus during infection is oversimplified. We therefore seek to gain a
greater fundamental understanding of how coinciding infections with P. aeruginosa
and S. aureus occur in CF patients in an effort to more effectively eliminate these
infections.
One hypothesis to explain coinciding P. aeruginosa-S. aureus infections in CF pa-
tients is spatial segregation of these species during infection, such that P. aeruginosa
antimicrobials are unable to access and thereby kill S. aureus during infection. For
example, utilizing a wound-like model of P. aeruginosa-S. aureus coinfection, DeLeon et
al. established species coexistence for up to 7 days (21). The authors attribute S. aureus
survival to the spatial separation of these species established during biofilm formation
in this model. Moreover, physical separation between P. aeruginosa and S. aureus
microcolonies has been observed in human wound biopsy specimens (22). For CF
pulmonary infections, recent studies suggest that P. aeruginosa and S. aureus may
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occupy the same airspace during infection. Hogan and colleagues identified P. aerugi-
nosa and S. aureus in the same lobes of the lung by examining protected brush samples
(23), and Wakeman et al. have presented histological evidence of bacteria with the
morphological characteristics of Pseudomonas and Staphylococcus infecting the same
niche in explanted lungs from a CF patient (24). However, due to current technical
constraints studying in vivo infections, if and to what extent meaningful physical
interactions occur between these pathogens in the context of CF infections is com-
pletely unknown.
We therefore sought to design a study to gain insight into whether P. aeruginosa
and S. aureus may interact during infection and, if so, how such coexistence can occur
in light of the observation that P. aeruginosa can kill S. aureus in vitro. We reasoned that
P. aeruginosa may adopt phenotypes that limit its antagonism toward S. aureus. To test
this hypothesis, we first asked if P. aeruginosa isolates from CF patients were able to
outcompete S. aureus in vitro, as previously observed, and importantly if strains from
coinfected patients were less competitive than P. aeruginosa isolates obtained from
patients who were not infected with S. aureus. Consistent with this idea, we observed
that P. aeruginosa isolates from coinfected patients were more permissive to growth
with S. aureus than P. aeruginosa isolates from monoinfected patients. Investigation
into the nature of coexistence revealed that the presence of a mucoid phenotype
limited P. aeruginosa antimicrobial action toward S. aureus. We found that mucoidy
reduces the production of siderophores, HQNO, and rhamnolipids; each is required for
robust killing of S. aureus (7–16). Moreover, overproduction of the polysaccharide
alginate was sufficient to decrease the production of these key compounds. Together
these studies suggest that genotypic and phenotypic modifications of P. aeruginosa
during infection may contribute to coinfection with S. aureus.
RESULTS
P. aeruginosa isolates from coinfected CF patients are less antagonistic toward
S. aureus than isolates from monoinfected CF patients. In a previous study, we
investigated the clinical outcome of CF patients during coinfection with P. aeruginosa
and S. aureus. We observed that coinfection correlated with poor patient outcome,
including a decline in lung function, compared to monoinfected patients (17). To
investigate if there are differences in the isolates from these patients that may con-
tribute to establishing coinfection, we obtained 28 P. aeruginosa strains and 20 S. aureus
strains from patients who were either coinfected or monoinfected from the CF Bio-
specimen Registry (CFBR) at EmoryChildren’s Center for Cystic Fibrosis and Airways
Disease Research. Note that monoinfection refers to the absence of either P. aeruginosa
or S. aureus during the review year, but other pathogens may be present. Positive
cultures for Burkholderia, Stenotrophomonas, Achromobacter, Acinetobacter, Chryseobac-
terium, Klebsiella, Streptococcus spp., Haemophilus influenzae, and Escherichia coli were
recorded, but the frequencies of these other microbes were not sufficiently high to
establish significant correlations between the presence of individual microbes and
clinical outcomes.
Based on our previous findings showing worse clinical outcomes for coinfected
patients, we then asked the following question: do P. aeruginosa and S. aureus strains
from coinfected patients grow better in coculture than strains from monoinfected
patients? To address this question, each P. aeruginosa clinical isolate was challenged
with a laboratory strain of S. aureus (USA300 LAC, JE2) and S. aureus clinical isolates with
a laboratory strain of P. aeruginosa (PAO1) in an agar plate-based cross-streak assay.
Single colonies of S. aureus and P. aeruginosa were cross-streaked according the
schematic in Fig. 1a. Note that results were similar regardless of the order in which the
pathogens were cross-streaked: i.e., P. aeruginosa followed by S. aureus, or vice versa.
The interactions between the two species was examined by visually inspecting growth
at the intersection of the cross-streak and by determining the percentage of the
population of P. aeruginosa and S. aureus by recovering bacterial growth in the
poststreak (white arrowhead in Fig. 1a) and enumerating the number of CFU for each
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P. aeruginosa and S. aureus strain on selective media (Pseudomonas isolation agar [PIA]
and mannitol salts agar [MSA], respectively). The P. aeruginosa clinical isolates shown in
Fig. 1a are representative of the spectrum of P. aeruginosa inhibition of S. aureus,
ranging from most competitive on the left to least competitive on the right.
We found that P. aeruginosa clinical strains recovered from patients who were
monoinfected with P. aeruginosa on average outcompeted S. aureus strain JE2 (Fig. 1b),
and P. aeruginosa strains had a higher competitive index (CI [P. aeruginosa/S. aureus])
(Fig. 1d, leftmost bar). This pattern of competition was significantly different from that
observed for P. aeruginosa isolates from patients that were coinfected with S. aureus
(Fig. 1c), where the CI was on average 2-fold lower (Fig. 1d, second bar). However, when
S. aureus isolates from CF patients were screened by cross-streaking with P. aeruginosa
strain PAO1, no difference in the CI for S. aureus isolates was observed between mono-
and coinfected patients (see Fig. S1 in the supplemental material).
Mucoid conversion reduces P. aeruginosa inhibition of S. aureus. An additional
correlation was revealed during this screen, whereby P. aeruginosa isolates that exhib-
ited a mucoid phenotype displayed a CI 6-fold lower on average than that of nonmu-
coid isolates (Fig. 1d, right 2 bars). Mucoid conversion is generally characterized by
overproduction of the polysaccharide alginate, and the designations as nonmucoid and
FIG 1 P. aeruginosa isolates from coinfected CF patients are less competitive with S. aureus. (a) Schematic of the
method for cross-streak assay. S. aureus (USA300 LAC, JE2) was streaked onto tryptic soy agar followed by
cross-streaking with P. aeruginosa isolates (CFBRPA) from the CF Biospecimen Registry (CFBR) at EmoryChildren’s
Center for Cystic Fibrosis and Airways Disease Research. Coculture assays were performed by cross-streaking
P. aeruginosa CF isolates and S. aureus on an agar surface, and the percentage of the total population of
P. aeruginosa (gray bars) and S. aureus (white bars) recovered post-cross-streak (white arrowhead in panel a) were
enumerated by plating on selective media and dividing the number of P. aeruginosa or S. aureus CFU by the total
CFU (S. aureus plus P. aeruginosa). P. aeruginosa strains from panel b were isolated from CF patients who were
infected with only P. aeruginosa (monoinfection), and strains in panel c were isolated from patients who were
coinfected with P. aeruginosa and S. aureus. Mucoid and nonmucoid (nm) phenotypes are indicated. In panel d, a
summary of the competitive index (CI) of all P. aeruginosa strains is indicated according the patient group from
which they were isolated or their mucoid phenotype. CI was calculated by dividing the percentage of P. aeruginosa
by the percentage of S. aureus recovered in the post-cross-streak. Error bars indicate standard deviations from three
biological replicates performed in triplicate. Statistical significance was determined by performing an unpaired
two-tailed t test. **, P  0.001.
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mucoid in Fig. 1 were based on visual observation of alginate production of colonies
grown on agar. To test the hypothesis that conversion to the mucoid phenotype
promotes P. aeruginosa coexistence with S. aureus, isogenic P. aeruginosa mutants in
genes responsible for regulation of alginate synthesis were examined. Mucoid conver-
sion occurs most frequently in P. aeruginosa clinical strains via acquisition of mutations
in the anti-sigma factor gene mucA. In nonmucoid strains, intact MucA sequesters the
alternative sigma factor, 22 (AlgT/U), which is the primary regulator of alginate
production (25). In mucoid strains, inactivation of MucA (most frequently via the
mucA22 mutation, ΔG430, frameshift) results in release of AlgT, which is now free to
activate transcription of the alginate biosynthetic operon initiated at the algD promoter
(PalgD) (26). We therefore competed isogenic mutants of the primary regulators of
alginate synthesis in P. aeruginosa PAO1 with S. aureus JE2 to examine the contribution
of mucoid conversion to coexistence with S. aureus in the cross-streak assay. Consistent
with the correlations observed with P. aeruginosa clinical isolates, nonmucoid P. aerugi-
nosa PAO1 outcompeted S. aureus. In contrast, introduction of the mucA22 mutation in
PAO1, which confers a mucoid phenotype, reduced P. aeruginosa competition with
S. aureus (Fig. 2a). Next, to determine if constitutive activation of the sigma factor AlgT
as a result of MucA inactivation is responsible for the decreased competition of
P. aeruginosa, we disrupted the algT gene in the mucA22 mutant and observed restored
competition to wild-type (WT) levels. While alginate overproduction is the most visually
apparent phenotype in P. aeruginosa strains when the mucA gene is disrupted, AlgT
regulates a number of other factors that have been shown to contribute to competition
with S. aureus, including genes required for the synthesis of pyoverdine, pyochelin,
phenazines, and hydrogen cyanide (27–30). We would therefore hypothesize that AlgT
regulates antistaphylococcal factors independent of alginate overproduction. However,
when alginate production was selectively removed by disruption of algD (the first gene
in the alginate biosynthetic operon) in the mucA22 mutant, P. aeruginosa was now able
to outcompete S. aureus. This result suggests that alginate production may modulate
P. aeruginosa competition with S. aureus. These phenotypes were also reproduced in
the mucoid CF isolate FRD1 (mucA22) and its nonmucoid derivatives, FRD mucA22
algT33::TnS1 and FRD mucA22 algD::xylE (Fig. 2a).
To determine if mutations in mucA are responsible for the mucoid phenotype in a
representative mucoid isolate from a coinfected patient in this study, the genomic
sequence of the mucA gene from the clinical P. aeruginosa isolate CFBRPA43 was
examined. Indeed, strain CFBRPA43 possessed a mucA22 mutation, which would be
predicted to disrupt mucA function. To investigate the contribution of mucoid conver-
sion in isolate CFBRPA43, we isolated nonmucoid suppressors by serial passage in broth
culture and identified colonies displaying a nonmucoid phenotype. In CF, the most
frequent suppressor of mucoid mutations occur within the algT gene (31). We therefore
sequenced algT, confirmed the presence of a mutation in algT (S1, 8-nucleotide
insertion at position 138; S2, C245A), and compared the competition of two suppressors
to the mucoid parental strain in the cross-streak assay. As expected, the nonmucoid
variants outcompeted S. aureus compared to the mucoid parental strains (Fig. 2b).
These data demonstrate that alginate overproduction correlates with the loss of
P. aeruginosa-mediated inhibition of S. aureus and suggest that mucoid conversion may
be a factor promoting P. aeruginosa and S. aureus coexistence during CF respiratory
infections.
To determine if P. aeruginosa outcompetes S. aureus by inhibiting growth or
reducing S. aureus viability, P. aeruginosa and S. aureus competition was monitored in
shaking broth culture over the course of 8 h by enumerating P. aeruginosa and S. aureus
CFU on selective media (PIA and MSA, respectively) every 2 h. Similar to previous
studies, P. aeruginosa viability was not altered by the presence of S. aureus under any
of the conditions examined (10) (see Fig. S2a and b in the supplemental material). For
S. aureus, coculture with either mucoid or nonmucoid P. aeruginosa did not alter
viability or growth rate during the initial stages of growth. However, after approxi-
mately 4 h of competition, the viability of S. aureus drastically decreased in the presence
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of either nonmucoid strains, PAO1 or PAO1 mucA22 algD::FRT (FLP recombination
target) (with representative kinetic analysis shown in Fig. 2c). These data indicate that
nonmucoid P. aeruginosa is capable of killing S. aureus during competition and is not
simply inhibiting growth. On the other hand, no decrease in viability of S. aureus was
observed in the presence of the mucA22 mutant through the duration of the experi-
ment, indicating that alginate-overproducing strains have reduced ability to kill S. au-
reus. Identical results were observed when mucoid and nonmucoid P. aeruginosa strains
were grown in competition with S. aureus methicillin-sensitive strain Newman (Fig. S2c).
Mucoid conversion prevents P. aeruginosa killing of S. aureus during compe-
tition in models of CF respiratory infection. During CF pulmonary infections, both
P. aeruginosa and S. aureus exist in complex and dynamic communities that influence
their intra- and interspecies interactions (32, 33). Recently, we have established an in
vitro human airway cell— dual bacterial biofilm infection model, whereby P. aeruginosa
and S. aureus form mixed-species biofilms on monolayers of human bronchial epithelial
FIG 2 Mucoid conversion prevents P. aeruginosa killing of S. aureus. In vitro P. aeruginosa-S. aureus coculture assays
on tryptic soy agar (a and b) and broth (c), in biofilm growth on human CF bronchial epithelial cells (CFBE) (d and
e), and in synthetic CF sputum medium (f). In panels a and b, the percentages of the populations of P. aeruginosa
(gray) and S. aureus (white) recovered post-cross-streak are indicated. Isogenic P. aeruginosa PAO1 and FRD1
variants, with the mucA, algT, and algD genotypes and the mucoid phenotype indicated below (a), and mucoid
P. aeruginosa CFBRPA43 and nonmucoid suppressors (S1, nm and S2, nm) of P. aeruginosa CFRBPA43 (b) were
cross-streaked with S. aureus strain JE2. Panel c shows the viable count of S. aureus JE2 over time for the indicated
strains. In panels d, e, and f, the viability of S. aureus JE2 after 22 h of competition with the indicated P. aeruginosa
strains is indicated. Error bars indicate standard deviations from at least three biological replicates performed in
triplicate. Statistical significance was determined by performing an unpaired two-tailed t test. ***, P  0.0001.
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cells homozygous for the ΔF508 cystic fibrosis transmembrane conductance regulator
mutation (CFBE) (10, 34). To determine how alginate overproduction influences the
dynamics of interspecies interactions in this model, wild-type (WT) PAO1, mucA22, and
mucA22 algD::FRT strains were cocultured with S. aureus JE2 on CFBE cells for 22 h, and
CFU were enumerated at 6, 18, and 22 h. Similar to the observation in Fig. 2c for broth
culture, nonmucoid P. aeruginosa (both WT and mucA22 algD::FRT strains) coexists with
S. aureus early during culture, followed by a sharp decrease in S. aureus viability by 18 h
(representative kinetic CFU illustrated in Fig. S2d in the supplemental material and at
the 22-h time point in Fig. 2d). This finding is consistent with a previous report from our
group using nonmucoid P. aeruginosa strains PAO1 and PA14 cocultured with S. aureus
strain 8325-4 (10). In contrast, S. aureus viability is unaltered for the duration of the
experiment when cocultured with the mucA22 mutant. Additionally, representative
nonmucoid (CFBRPA40) and mucoid (CFBRPA43) P. aeruginosa clinical isolates, identi-
fied to be competitive and noncompetitive with S. aureus in the cross-streak assay,
respectively (Fig. 1c), were selected for analysis in this model. As predicted, nonmucoid
P. aeruginosa strain CFRBPA40 reduced the viability of S. aureus, compared to mucoid
P. aeruginosa strain CFBRPA43 (Fig. 2e). Finally, to investigate if nutrient availability in
the CF respiratory environment influences competitive dynamics between P. aeruginosa
and S. aureus, coculture growth was monitored in synthetic CF sputum medium (35). In
accordance with prior observations, S. aureus viability was reduced during growth with
nonmucoid P. aeruginosa (PAO1), but remained unaltered in the presence of mucoid
P. aeruginosa (PAO1 mucA22) (Fig. 2f). These data demonstrate that mucoid conversion
supports P. aeruginosa-S. aureus coexistence in mixed-species communities during
growth in models that mimic the CF respiratory environment.
Induction of alginate reduces P. aeruginosa antimicrobial activity independent
of AlgT activation. The data presented thus far demonstrate that mucoid conversion
limits the ability of P. aeruginosa to reduce S. aureus viability; however, whether
overproduction of alginate by P. aeruginosa is sufficient for this interaction is unclear.
Therefore, to study this behavior in more detail, we sought to engineer a P. aeruginosa
strain whereby alginate production can be modulated in a nonmucoid strain with intact
mucA. Such a strategy would allow us to assess the influence of alginate overproduc-
tion on P. aeruginosa physiology and gene expression, without the activation of the
entire AlgT regulon. Alginate is a high-molecular-weight acidic polysaccharide com-
posed of nonrepeating subunits of selectively O-acetylated D-mannuronic acid and its
C5= epimer, L-guluronic acid (36). Genes required for alginate biosynthesis are primarily
organized within a single operon (algD, -8, -44, -K, -E, -G, -X, -L, -I, -J, -F, and -A), with the
exception of the algC gene (see the schematic in Fig. 3a). algC encodes a phospho-
mannomutase required to convert mannose-1-phosphate to mannose-6-phosphate
(37). To engineer a strain that bypasses the need for AlgT activation of these genes
(schematic in Fig. 3b), we replaced the promoter of the alginate biosynthetic operon
(PalgD) with an arabinose-inducible promoter (araC-ParaBAD) on the chromosome of
nonmucoid strain PAO1. Additional regulation of alginate synthesis occurs at the
posttranscriptional level, whereby polymerization by the inner membrane proteins
Alg8 and Alg44 requires binding of the second messenger bis-(3=,5=)-cyclic dimeric GMP
(c-di-GMP) to Alg44 (38). In mucA mutants, the requisite c-di-GMP would be provided
through the action of diguanylate cyclases activated by AlgT. To circumvent the need
for AlgT activation, PalgD::araC-ParaBAD was constructed in a mutant with constitutively
high levels of c-di-GMP (PAO1 ΔwspF) (39).
To determine if PAO1 ΔwspF PalgD::araC-ParaBAD (abbreviated “PAO1algIND,” for
“PAO1 alginate inducible,” from this point forward) produces alginate only in the
presence of arabinose under the conditions utilized in the coculture assays,
PAO1algIND was grown with and without 0.5% arabinose for 8 h in a shaking broth
culture, and the amount of alginate produced was determined by a standard carbazole
assay. (Growth rates for both P. aeruginosa and S. aureus were identical with and
without arabinose.) Alginate production increased by approximately 2-fold in the
presence of 0.5% arabinose (9.3 g/optical density at 600 nm [OD600]) compared to
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without arabinose, demonstrating alginate synthesis can be induced using this
strategy (Fig. 3c). The increase in alginate production was modest however com-
pared to PAO1 mucA22 (153.4 g/OD600) (Fig. 3c; note y axis). To determine if this
level of alginate production is sufficient to prevent P. aeruginosa-mediated reduc-
tion of S. aureus viability, PAO1algIND was grown with and without arabinose in the
presence of S. aureus. Without arabinose, PAO1algIND reduced the viability of
S. aureus by ~1,000-fold by 8 h, whereas in the presence of 0.5% arabinose, S. aureus
viability was maintained for the 10 h of the assay period (Fig. 3d and e). The time
required for uninduced PAO1algIND to initiate killing of S. aureus was longer than
observed for PAO1 (8 h compared to 4 h [Fig. 2c]). Overall, however, the sustained
viability of S. aureus observed when competed with PAO1algIND plus arabinose
supports the previous observation that alginate prevents P. aeruginosa killing of
S. aureus. Furthermore, our analysis of the PAO1algIND strain suggests that the amount
of alginate produced by PAO1 mucA22 is in excess of the amount required to reduce
killing of S. aureus.
Alginate overproduction reduces the expression of a subset of P. aeruginosa
virulence genes. P. aeruginosa secretes several antistaphylococcal effectors which can
inhibit respiration (hydrogen cyanide, quinolones, and phenazines) and sequester iron
(siderophores) (7–16). To determine how alginate overproduction prevents P. aerugi-
nosa from killing S. aureus, we asked if alginate overproduction alters the expression
FIG 3 P. aeruginosa alginate production promotes coexistence with S. aureus. (a) Abbreviated schematic
of alginate regulation in P. aeruginosa. Disruption of MucA results in release of AlgT, activating
transcription of the algC gene, genes encoded in the alginate biosynthetic operon (alg operon, under
control of the algD promoter PalgD), and bis-(3=,5=)-cyclic dimeric GMP (c-di-GMP)—all required for
alginate synthesis. (b) Schematic of alginate regulation in P. aeruginosa PAO1 ΔwspF PalgD::araC-ParaBAD
(PAO1algIND), whereby PalgD was replaced by araC-ParaBAD, to place the alg operon under inducible
control of arabinose. Deletion of wspF results in inhibition of WspR and production of c-di-GMP. In panel
c, alginate was extracted from nonmucoid wild-type PAO1 (WT) and the PAO1 mucA22, PAO1 mucA22
algD::FRT, and PAO1algIND mutants grown without arabinose (0% ara) and with 0.5% arabinose (0.5%
ara) and quantified by a standard carbazole assay. In panels d and e, the log10 CFU/ml for S. aureus JE2
are indicated when grown in the presence of PAO1algIND without (open circles) and with (solid circles)
0.5% arabinose for 10 h (d); S. aureus log10 CFU/ml at 8 h are shown only in panel e. Error bars indicate
standard deviations from four biological replicates performed in triplicate. Statistical significance was
determined by performing an unpaired two-tailed t test. **, P  0.01.
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profile of genes associated with physiological pathways important for S. aureus inter-
actions and infection in the CF airway. We utilized NanoString digital multiplexed gene
expression technology (40, 41) to quantify the expression level of P. aeruginosa mRNA
transcripts in mucoid PAO1 mucA22 compared to nonmucoid PAO1 mucA22 algD::FRT,
as well as PAO1algIND grown with and without arabinose. We utilized gene-specific
probes described previously (NanoString codeset PAV2) that monitor the expression of
75 transcripts associated with biofilm formation, polysaccharide production, iron ac-
quisition, quorum sensing, and virulence (41). In brief, transcripts were monitored using
a set of two hybridization probes complementary to each transcript of interest, with
one probe enabling the capture of the transcript and the other containing a unique
fluorescent barcode for direct transcript enumeration that reflects abundance in the
sample.
To assess changes in P. aeruginosa transcript profiles during alginate production, the
relative levels of expression for each gene in the PAV2 NanoString codeset were
compared between PAO1 mucA22 and PAO1 mucA22 algD::FRT (Fig. 4a), as well as
PAO1algIND with and without arabinose to induce alginate production (Fig. 4b).
Differences in raw transcript levels were also analyzed by their ranked abundance (heat
map shown in Fig. S3a and raw data in Table S1 in the supplemental material). The
relative transcript levels of five genes in the codeset were significantly lower (rhlA, norC,
fliC, pvdA, and pchC) in the mucA22 mutant compared to the mucA22 algD::FRT mutant
(Fig. 4a). As expected, we observed significantly higher levels of algD transcript in the
mucA22 compared to the mucA22 algD::FRT strain. However, a larger amount of algI was
also observed. This observation could be a result of inactivation of downstream genes
in the alginate biosynthetic operon in the mucA22 algD::FRT strain or from the acqui-
sition of a secondary mutation in algT during the construction of the algD::FRT strain.
To confirm that algT has not been altered in this strain, the sequences of algT in PAO1
mucA22 and PAO1 mucA22 algD::FRT were compared and confirmed to be identical.
The expression of algT and the subset of AlgT-regulated genes examined here were
also not significantly different between these strains, confirming that alginate produc-
tion is reduced in PAO1 mucA22 algD::FRT, but it retains constitutive expression of algT
(see Table S2 in the supplemental material). In concordance with the comparison of the
FIG 4 Alginate overproduction decreases the expression of P. aeruginosa genes required to reduce S. aureus
viability. Relative expression of a subset of P. aeruginosa virulence genes was compared in PAO1 mucA22 (mucoid)
and PAO1 mucA22 algD::FRT (nonmucoid) strains (a) and PAO1algIND strains grown with (mucoid) and without
0.5% arabinose (ara) (nonmucoid) (b) by the NanoString nCounter analysis system. The abundance of 75 transcripts
was examined with a custom-designed codeset. Transcripts were log2 transformed and normalized to two
P. aeruginosa housekeeping genes (rpoD and ppiD). Genes determined to be significantly differentially regulated
when alginate is produced by an unpaired t test followed by the two-stage linear step-up procedure of Benjamini,
Krieger, and Yekutieli (with q  1% for false discovery) are indicated in red. Genes involved in the PQS pathway
are indicated with open circles.
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mucoid mucA22 mutant and its nonmucoid derivative PAO1 mucA22 algD::FRT, tran-
script levels of rhlA, norC, pvdA, and pchC were lower in PAO1algIND when grown in the
presence of arabinose (and thus producing alginate), compared to without this inducer
(Fig. 4b). While transcript levels of fliC were also lower, the difference was not statisti-
cally significant. The relative expression of algD in PAO1algIND in the presence of
arabinose was less than the expression in PAO1 mucA22, which corresponds to the
modest increase in alginate production observed in Fig. 3c for the alginate-inducible
strain. Accordingly, a smaller change in the relative expression of the rhlA, pvdA, pchC,
and norC genes was also observed. Finally, gene expression profiles for P. aeruginosa
when grown in competition with S. aureus were examined, and no significant difference
in gene expression was observed (Table S1), as we reported previously using transcrip-
tome sequencing (RNA-Seq) analysis (10).
Alginate overproduction reduces pyoverdine production. mRNA analysis re-
vealed that expression of genes required for siderophore production (pvdA and pchC,
for the synthesis of pyoverdine and pyochelin, respectively) were lower when alginate
was overproduced. These siderophores specifically chelate iron (Fe3), a role previously
demonstrated to be involved in P. aeruginosa inhibition of S. aureus growth (8, 10). We
therefore determined if pyoverdine (the predominant P. aeruginosa siderophore) plays
a role in inhibiting growth of S. aureus under the conditions utilized in this study. We
first confirmed reduced expression of pvdA in the mucA22 mutant compared to the WT
and mucA22 algD::FRT strains by quantitative real-time PCR (qRT-PCR) (Fig. S3b).
We then competed P. aeruginosa deficient in pvdA with S. aureus and observed a
significant but modest restoration of S. aureus viability compared to the WT (Fig. 5a), as
previously reported (10). We then asked if the observed decrease in pvdA expression
when alginate is overproduced, results in decreased pyoverdine production. Pyover-
dine is fluorescent when excited at 400 nm, and we utilized this property to determine
the amount of pyoverdine produced as measured in relative fluorescent units (RFU) per
OD600 of P. aeruginosa cultures grown for 8 h under the conditions utilized in the
coculture assays. The mucA22 mutant produced approximately 40% less pyoverdine
than nonmucoid, WT P. aeruginosa. When algD is deleted in the mucA22 mutant,
pyoverdine production is restored (Fig. 5b), demonstrating that pyoverdine levels are
lower in alginate-producing P. aeruginosa strains.
Alginate overproduction reduces HQNO production. In addition to siderophores,
we and others previously reported that 2-heptyl-4-hydroxyquinoline-N-oxide (HQNO)
inhibits S. aureus respiration (7, 10, 42), and we further showed that HQNO causes a shift
to a fermentative lifestyle and eventual S. aureus cell death during late stage biofilm
growth on CFBE cells (10). In our NanoString studies described above, we did not
observe a significant change in the expression of genes involved in the Pseudomonas
quinolone signal pathway (pqs) in alginate-overproducing strains (open circles in Fig. 4a
and b and heat map in Fig. S3a). The PqsA to -E, -L, and -H enzymes catalyze the
synthesis of a series of 4-hydroxy-2-alkylquinolones (HAQs [schematic in Fig. 5c]) (15,
43). Anthranilic acid is converted by PqsA and -D to a series of precursors whose precise
structures are unknown (indicated by brackets), and these intermediates are ultimately
converted to either 4-hydroxy-2-heptylquinoline (HHQ) by PqsB and -C (which can be
converted to 3,4-dihydroxy-2-heptylquinoline [PQS] by PqsH) or converted to HQNO by
PqsL (15). Because deletion of pqsL reduces the ability of P. aeruginosa to kill S. aureus
compared to the wild type (10) (see Fig. S4 in the supplemental material), we would
have predicted that alginate overproduction might decrease expression of genes
involved in HQNO synthesis, reducing the amount of HQNO produced by mucoid cells.
While P. aeruginosa HQNO production peaks in late stationary phase, the expression of
the genes encoding enzymes required for HQNO generation peaks in late exponential
phase (15). For the NanoString analysis, RNA was extracted from P. aeruginosa cells in
late stationary phase. We therefore examined the expression of pqsL by qRT-PCR at
various time points in WT PAO1 compared to a P. aeruginosa PAO1 pqsL64 mutant,
previously characterized to be deficient in the production of HQNO (44). pqsL expres-
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sion peaked for WT in late exponential phase (3 h, OD600 of ~1.8) (Fig. S3c), as
previously observed (15). Expression of pqsL was then examined in the mucA22 mutant
at ~3 h and was found to be modestly but significantly decreased in relative expression
compared to mucA22 algD::FRT (Fig. S3d). To determine if HQNO generation is altered,
we measure HQNO present in culture supernatants of P. aeruginosa by extracting
HQNO from equal cell numbers of P. aeruginosa strains, including the WT and the
ΔpqsA, mucA22, and mucA22 algD::FRT mutants, and quantified HQNO by liquid chro-
matography coupled to mass spectrometry (LC-MS), as previously described (45).
FIG 5 Alginate overproduction inhibits antistaphylococcal exoproducts. (a) In vitro P. aeruginosa-
S. aureus coculture assays in planktonic culture with the indicated strains. Log10 CFU/ml for S. aureus JE2
are indicated after 8 h of incubation. (b) Pyoverdine was quantified as relative fluorescence units
(RFU)/OD600 produced by planktonic P. aeruginosa strains grown for 8 h. (c) Schematic of 2-heptyl-4-
hydroxyquinoline-N-oxide (HQNO) synthesis. The PqsA to -E, -L, and -H enzymes catalyze the synthesis
of a series of 4-hydroxy-2-alkylquinolones (HAQs). The conversion of anthranilic acid to uncharacterized
intermediates (indicated by the brackets) is catalyzed by PqsA and -D, followed by conversion to either
4-hydroxy-2-heptylquinoline (HHQ) by PqsB and -C (which can be converted to 3,4-dihydroxy-2-
heptylquinoline [PQS] by PqsH) or converted to HQNO by PqsL. (d) HQNO quantification by LC-MS from
supernatants derived from the indicated strains following 8 h of incubation in planktonic culture and (e)
in vitro P. aeruginosa-S. aureus coculture assays in planktonic culture with P. aeruginosa PAO1 pqsL64
(white) and PAO1 mucA22 (gray) in the presence of the indicated concentrations of HQNO. Log10 CFU/ml
for S. aureus JE2 are indicated after 19 h of incubation. Error bars indicate standard deviations from three
biological replicates performed in triplicate. In panels a and b, statistical significance was determined by
performing an analysis of variance (ANOVA) followed by a Dunnett’s multiple comparison test comparing
each condition to the WT in panels a and d (*, P  0.05; **, P  0.01; ***, P  0.0001) and to JE2 only
in panel b. In panel e, statistical significance was determined by performing independent ANOVA
analyses for PAO1 pqsL64 and PAO1 mucA22 followed by a Dunnett’s multiple comparison test com-
paring the viability of S. aureus JE2 in the presence of each HQNO concentration to the condition without
HQNO, and the viability was significantly decreased at each concentration: for PAO1 pqsL64; P  0.0001,
and for PAO1 mucA22, P  0.01.
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Nonmucoid WT P. aeruginosa produced approximately 0.80 g/ml of HQNO, whereas
the mucoid mucA22 mutant produced 0.12 g/ml HQNO, a significant reduction
(Fig. 5d). No HQNO was detected in the ΔpqsA mutant, the negative-control strain.
Deletion of algD in the mucA22 mutant restored the production of HQNO to levels that
are significantly increased compared to those of the wild type (0.98 g/ml).
To confirm that reduced HQNO in the mucA22 mutant contributes to decreased
killing of S. aureus, we asked if the addition of exogenous HQNO could restore killing
of S. aureus. As a control, we first tested if the addition of HQNO could complement a
pqsL mutant. As expected, pqsL64 was unable to reduce S. aureus viability (Fig. 5e;
Fig. S4C), supporting previous observations that HQNO is required to kill S. aureus (7, 10,
42). We then grew S. aureus in monoculture or in coculture with the P. aeruginosa WT,
pqsL64, or mucA22 strain with either 12.5 g/ml HQNO or dimethyl sulfoxide (DMSO)
(vehicle control). The addition of HQNO did not affect the viability of S. aureus alone or
in the presence of wild-type P. aeruginosa PAO1 (Fig. S4a and b) but did restore killing
mediated by the pqsL64 mutant (Fig. S4c), albeit the amount of time to initiate killing
was delayed compared to that with WT P. aeruginosa. Importantly, HQNO partially
restored the ability of the P. aeruginosa mucA22 mutant to kill S. aureus (Fig. S4d),
suggesting decreased production of HQNO contributes to the reduced antimicrobial
activity of the mucoid isolates. The addition of HQNO did not fully restore killing of
S. aureus by the PAO1 mucA22 strain, and the concentrations required to restore killing
were higher for mucA22 compared to pqsL64 (Fig. 5e).
Rhamnolipids contribute to P. aeruginosa killing of S. aureus. NanoString anal-
ysis of alginate-overproducing strains also revealed lower transcript levels of rhlA
compared to those in nonmucoid strains: rhlA is the gene that encodes the first enzyme
required for the synthesis of P. aeruginosa surfactants (rhamnolipids) (Fig. 4a and b).
RhlA is involved in the synthesis of the fatty acid dimer 3-(3-hydroxyalkanoyloxy)
alkanoic acid (HAA) moiety of rhamnolipids from 3-hydroxy fatty acid precursors, which
are subsequently converted to monorhamnolipids, and dirhamnolipids, by RhlB and
RhlC, respectively (46). HAA, mono-, and dirhamnolipids each have biosurfactant
activity, but the type of rhamnolipid produced and the amount depends on the strain
and the carbon source (47). Rhamnolipids derived from P. aeruginosa strains isolated
from oil-contaminated soil have been shown to have antimicrobial activity against
S. aureus (13, 14); therefore, we hypothesized that the production of rhamnolipids may
also play a role in P. aeruginosa interactions with S. aureus in our model. We first
confirmed reduced expression of rhlA in the mucA22 mutant compared to the WT and
mucA22 algD::FRT mutant by qRT-PCR (Fig. S3e). Furthermore, when the rhlA gene was
disrupted in P. aeruginosa (PAO1 rhlA::Gm), the viability of S. aureus in coculture was
similar to that seen with mucA22 mutant (Fig. 6a).
To determine if rhamnolipid production is also decreased when alginate is overpro-
duced, we assayed for biosurfactant activity in clarified P. aeruginosa supernatant from
the mucoid mucA22 mutant compared to the nonmucoid, WT, and mucA22 algD::FRT
strains, utilizing a drop collapse assay, as previously described (48). In brief, the
presence of sufficient surfactant disrupts the surface tension of droplets of bacterial
supernatant on plastic, which will migrate downward when placed at a 90° angle.
Supernatant from each strain (or purified rhamnolipid) was serially diluted 2-fold, and
the surfactant activity calculated as 1/dilution at which the drop begins to migrate (see
representative images in Fig. S5 and quantification of biological replicates in Fig. 6b).
P. aeruginosa WT supernatant, which produces rhamnolipids, exhibits surfactant activity
of approximately 3.5, compared to 0.5 when rhlA is disrupted (Fig. 6b). The surfactant
activity of PAO1 mucA22 phenocopies the rhlA mutant, and surfactant activity is
restored in the mucA22 algD mutant, demonstrating that alginate overproduction
reduces surfactant production in P. aeruginosa. A representative image of each strain at
the 1/8 dilution in shown in Fig. 6c. We then evaluated the ability of rhamnolipids to
kill S. aureus. We found that 100 g/ml of a 50/50 mixture of mono- and dirhamnolipids
reduces the viability of S. aureus from approximately 1  1010 CFU/ml to 1  106
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CFU/ml (Fig. 6d). Whereas the addition of exogenous rhamnolipids to S. aureus in the
presence of a rhlA mutant or the mucA22 mutant further reduces S. aureus viability to
below 100 CFU/ml, which supports our findings that multiple P. aeruginosa antimicro-
bials are required to kill S. aureus.
DISCUSSION
From our studies, we are able to begin to generate a model of how P. aeruginosa
and S. aureus may be able to coinfect the same niche in the respiratory tract of CF
patients (Fig. 7). During infection P. aeruginosa acquires mutations in the mucA gene,
leading to alginate overproduction. Alginate overproduction reduces the generation of
siderophores, HQNO, and rhamnolipids by lowering the expression of genes encoding
enzymes required for their generation. All three of these factors—HQNO, siderophores,
and rhamnolipids— have documented effects in reducing the viability of S. aureus
(7–16). These data demonstrate that the production of this polysaccharide is sufficient
to block a range of antimicrobials required for reduction of S. aureus viability. The
observations that PAO1algIND has reduced ability to kill S. aureus when grown in the
presence of arabinose, while only producing a modest level of alginate, suggests that
small changes in alginate production during infection could influence polymicrobial
dynamics. In agreement with this idea, we observed increased production of both
pyoverdine and HQNO compared to the WT when alginate production was completely
removed by deletion of algD (Fig. 5b and d). Evidence that even nonmucoid P. aerugi-
nosa strains produce alginate during CF pulmonary infections (41, 49) suggests that the
FIG 6 Alginate inhibits the production of rhamnolipids required to kill S. aureus. In vitro P. aeruginosa-
S. aureus coculture assays in planktonic culture. In panels a and d, the log10 CFU/ml for S. aureus JE2 are
indicated after 8 h of incubation, and in panels b and c, the drop collapse assay was used to measure
surfactant activity. Clarified supernatants were serially diluted (1:1) with water plus 0.005% crystal violet
for visualization. Twenty microliters of each dilution was spotted onto the underside of the lid of a petri
plate and tilted at a 90° angle. As surfactant quantities are reduced by dilution, surface tension increases,
resulting in the beading of the droplet. Surfactant scores are equal to the reciprocal of the greatest
dilution at which there was surfactant activity (a collapsed drop that migrates down the plate).
Quantification is indicated in panel b, and a representative image of all strains at the 1/8 dilution is shown
in panel c. In panel d, competitions were performed in the presence of the indicated concentrations of
rhamnolipids. Error bars indicate the standard deviation of three biological replicates performed in
triplicate (two biological replicates for panel d). In panels a and b, statistical significance was determined
by performing an ANOVA followed by a Dunnett’s multiple comparison test comparing each condition
to JE2 in panel a and to the WT only in panel b. In panel d, statistical significance was determined by
performing an ANOVA followed by a Tukey’s multiple comparison test to compare the mean survival of
S. aureus in the presence of each rhamnolipid concentration within strains. *, P  0.05; **, P  0.01; ***,
P  0.0001.
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observations in this study may be relevant beyond P. aeruginosa isolates that visibly
produce alginate.
The correlations identified herein through studying P. aeruginosa isolates from
coinfected CF patients support the hypothesis that one way P. aeruginosa and S. aureus
coexist in the CF lung is through P. aeruginosa reducing antimicrobial generation,
driven by alginate overproduction. While we are beginning to advance our knowledge
of the distribution of microbial species during CF pulmonary infections, and how and
to what extent interspecies interactions occur (50, 51), our understanding remains quite
limited. We predict that in certain areas of the lung, P. aeruginosa and S. aureus are
spatially segregated, which also likely contributes to S. aureus survival of during
coinfection, independent of P. aeruginosa competitive phenotypes. Thus, it is necessary
to further investigate the extent of spatial interspecies coexistence in CF, and its
influence on microbial physiology and patient outcome. If the former hypothesis is
supported, that P. aeruginosa adapts to the presence of competing species, we can
explore if such adaptations are specific to S. aureus. Reported studies from the Whiteley
group suggest that P. aeruginosa senses and responds to N-acetylglucosamine (GlcNAc)
shed from the cell wall of Gram-positive organisms (52); therefore, some specificity of
response may be afforded to Gram-positive organisms.
Our expression analysis revealed alginate-overproducing strains decrease expres-
sion of genes required for pyoverdine, HQNO, and rhamnolipid synthesis, as well as
norC, encoding a nitric oxide reductase, and fliC, encoding flagellin type B. We predict
alginate may also exert effects on additional P. aeruginosa genes not examined in this
study. Each gene identified here has been reported previously to be directly or
indirectly regulated by AlgT (27–30). Our data support a mechanism of indirect regu-
lation, whereby AlgT activates transcription of PalgD, resulting in increased alginate
production, which reduces the expression of a subset of genes in the AlgT regulon. In
agreement with a model of alginate-dependent regulation independent of AlgT, we did
not observe changes in algT gene expression (or additional genes analyzed known to
be AlgT regulated) in the mucA22 algD::FRT mutant compared to the mucA22 strain or
in PAO1algIND with and without arabinose (Fig. 3; Table S2). However, it remains a
formal possibility that limiting alginate production reduces posttranscriptional AlgT
activity and alters expression of only a subset of AlgT-regulated genes.
The mechanism by which alginate might reduce expression of genes required for
HQNO, siderophore, and rhamnolipid biosynthesis has not been established, yet mod-
ulation of relevant P. aeruginosa physiology by this polysaccharide is not unprece-
dented. Indeed, a recent report demonstrated alginate can interfere with PQS signal-
ing—a feature limited to alginate producers; no such inhibition of signaling was
FIG 7 Proposed model of P. aeruginosa coinfection with S. aureus. Nonmucoid isolates produce a range
of antimicrobial agents that can kill S. aureus, including siderophores, rhamnolipids, and HQNO, which
allows P. aeruginosa to outcompete S. aureus. If P. aeruginosa acquires mucA mutations during infection
leading to overproduction of the polysaccharide alginate, the expression of genes required for sidero-
phore, HQNO, and rhamnolipid synthesis are decreased. These modifications reduce the capacity of
P. aeruginosa to outcompete S. aureus, and the two species coexist in the CF lung.
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observed for the non-alginate-producing neighbors (53). Alginate has also been shown
to restrict the diffusion of oxygen (54–56) and aminoglycoside antibiotics (57), and to
bind and sequester reactive intermediates and iron (58). These properties may explain
how alginate is able to reduce the production of multiple P. aeruginosa virulence
factors. In the case of siderophores, alginate may help concentrate iron locally thus
reducing the need to acquire iron via siderophores. Prior studies demonstrating
increased alginate production during iron starvation support the hypothesis that
alginate aids P. aeruginosa in acquiring iron (59). In this scenario, we may predict that
changes in siderophore gene expression occur as part of derepression of the entire Fur
regulon. However, in our NanoString studies, we did not observe a significant change
in the expression of other Fur-regulated genes within the PaV2 codeset (bfrB, hasR,
phuR, and feoB). Alginate might also help to sequester other secreted factors thus
increasing their local concentration and feedback inhibiting their production, or mak-
ing such secreted factors unavailable to the cell. Alternatively, the draw on metabolites
to synthesize alginate may deplete intermediates used by other pathways. Such an
explanation may inform the reduction in rhamnolipid production, as these surfactants
require similar activated sugars for their synthesis. Whether via common or discrete
mechanisms, it is clear that production of even a small amount of alginate results in
markedly altered cellular physiology.
Our investigation of polymicrobial dynamics in CF isolates reinforces previous
observations (10) that in order for P. aeruginosa to kill S. aureus, multiple secreted
factors must be generated simultaneously by P. aeruginosa, as deletion of any one of
these factors reduces P. aeruginosa ability to kill S. aureus. These antimicrobials may
function individually and/or work together to enhance killing. For example, rhamno-
lipids have been shown to not only have antimicrobial activity, but these surfactants
can increase the solubility and activity of other P. aeruginosa metabolites such as PQS
(60). A recent report examined S. aureus-P. aeruginosa interactions in a biofilm coculture
model in a flow chamber system where the P. aeruginosa exoproducts required for
killing would be removed (61). Here the authors observed that nonmucoid P. aerugi-
nosa facilitates S. aureus biofilm formation, whereas mucoid P. aeruginosa tend to
outcompete S. aureus. This finding highlights the complexity of interspecies interac-
tions and how environmental conditions may influence such interactions. In CF respi-
ratory infections, microbial communities often persist in thickened, static airway
secretions and in close proximity to airway epithelial cells, and the P. aeruginosa
antimicrobials described here have not only been detected in the airway of CF patients
but may be predictors of airway infection (62, 63). We therefore predict these secreted
P. aeruginosa factors are important mediators of infection in CF respiratory disease.
Finally, whether the correlation observed between reduced competition by P. aerugi-
nosa and coinfection results from P. aeruginosa adapting in response to the presence
of competing species or that reduced competition by P. aeruginosa occurs indepen-
dently, which then permits growth of other organisms, is currently unknown.
Generation of a complete understanding of the dynamics of respiratory infections is
complicated by shifting host pathogens, as well as inter- and intraspecies interactions.
Here we revealed that a prevalent P. aeruginosa adaptation during chronic infections,
mucoid conversion, correlates with reduced P. aeruginosa competition with S. aureus.
Interrogation of this phenotype in vitro informed how mucoid conversion limits
P. aeruginosa competition with S. aureus— by reducing production antistaphylococcal
factors. Combining these findings with a model of coinfection during biofilm formation
on CF bronchial epithelia cells allows us to gain a more complete understanding of how
bacteria interact during infection.
MATERIALS AND METHODS
Bacterial strains and growth conditions. The bacterial strains used in this study are listed in
Table S3 in the supplemental material. P. aeruginosa and Escherichia coli were routinely grown in
lysogeny broth (LB) and S. aureus in tryptic soy broth (TSB), with 1.5% agar for solid medium. Synthetic
CF sputum medium was made as previously described (35) with 0.5% mucin. Gentamicin at 30 g/ml and
carbenicillin at 250 g/ml were used for P. aeruginosa, and 100 g/ml ampicillin was used for E. coli
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where indicated. Detailed descriptions of the construction of P. aeruginosa mutants can be found in
Text S1 in the supplemental material.
Coculture assays. P. aeruginosa and S. aureus were cocultured on either agar plates, in shaking broth
culture in rich medium (TSB) or synthetic CF sputum medium, or in biofilm growth on CF bronchial
epithelial cells. At the indicated time points, aliquots of culture were removed, and P. aeruginosa and
S. aureus were enumerated by plating on selective media (Pseudomonas isolation agar [PIA] and mannitol
salts agar [MSA], respectively). Detailed methods are provided in Text S1.
Alginate quantification. Alginate was collected from cultures grown as described above for
planktonic coculture assays and isolated as previously described (64), with modifications (65). Detailed
protocols can be found in Text S1.
NanoString analysis of P. aeruginosa transcripts. RNA transcript levels were measured using the
NanoString nCounter system (NanoString Technologies, Seattle, WA) and methods described by Geiss et
al. (66). We employed a custom-designed codeset containing 75 P. aeruginosa genes (Table S1). The
nucleotide sequences were provided to NanoString Technologies, Inc., for codeset design and construc-
tion. Each reaction mixture contained 70 ng of RNA, hybridization buffer, reporter probes, capture
probes, as well as six positive and eight negative controls. RNA was hybridized with reporter and capture
probes overnight at 65°C, and sample preparation ensued at the NanoString preparation station. Finally,
targets were counted on the nCounter using 255 fields of view per sample. Data were analyzed using
nSolver Analysis software, version 1.1 (NanoString Technologies, Seattle, WA). Raw counts were cali-
brated to the arithmetic mean of six spiked positive-control transcripts, and count values greater than 2
standard deviations above the average of the eight negative-control probes were considered above
background. Detailed protocols for RNA isolation and quantitative real-time PCR can be found in Text S1.
P. aeruginosa antimicrobial quantification. Pyoverdine, HQNO, and rhamnolipids were quantified
as previously described (45, 48, 67), respectively. Detailed protocols can be found in Text S1.
Availability of data. The authors certify that they will comply with mBio’s data policy: data will be
made publicly available upon publication and upon request for peer review.
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